Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

Studied

Randomized trial comparing semaglutide with placebo for major cardiovascular events.

Who / model

17,604 adults aged 45 or older with cardiovascular disease and overweight or obesity, without diabetes; average follow-up was 39.8 months.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The primary combined outcome—cardiovascular death, nonfatal heart attack or nonfatal stroke—occurred in 6.5% with semaglutide versus 8.0% with placebo. Adverse events led 16.6% versus 8.2% to permanently stop treatment.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary